InMed Pharmaceuticals (INM) Institutional Ownership $2.28 +0.06 (+2.70%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.27 -0.01 (-0.44%) As of 08/22/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for InMed Pharmaceuticals (NASDAQ:INM)CurrentInstitutional OwnershipPercentage20.12%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$3.29M Get INM Insider Trade Alerts Want to know when executives and insiders are buying or selling InMed Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data INM Institutional Buying and Selling by Quarter InMed Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025 AdvisorShares Investments LLC38,460$177K0.0%-94.8%5.342% 2/13/2024 Armistice Capital LLC205,968$86K0.0%N/A3.916% 11/14/2022 Armistice Capital LLC90,000$593K0.0%-90.6%9.605% 5/17/2022Empery Asset Management LP61,741$58K0.3%N/A0.437% 8/17/2021 Armistice Capital LLC890,000$2.83M0.1%+278.7%9.954% 8/12/2021 Penserra Capital Management LLC19,912$49K0.0%N/A0.223% 5/21/2021 Citadel Advisors LLC17,211$57K0.0%N/A0.214% (Data available from 1/1/2016 forward) INM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INM shares? During the previous two years, the following institutional investors and hedge funds held shares of InMed Pharmaceuticals shares: AdvisorShares Investments LLC ($177K), Armistice Capital LLC ($86K).Learn more on InMed Pharmaceuticals' institutional investors. What percentage of InMed Pharmaceuticals' stock is owned by institutional investors? 20.12% of InMed Pharmaceuticals' stock is owned by institutional investors. Learn more on INM's institutional investor holdings. Which institutional investors have been buying InMed Pharmaceuticals' stock? The following institutional investors have purchased InMed Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($205.97K). Which of InMed Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold InMed Pharmaceuticals stock in the last 24 months: AdvisorShares Investments LLC ($694.84K). How much institutional selling is happening at InMed Pharmaceuticals? Institutional investors have sold a total of 694,836 shares in the last 24 months. This volume of shares sold represents approximately $3.29M in transactions. Related Companies IMNN Major Shareholders NRSN Major Shareholders TRIB Major Shareholders MTEX Major Shareholders LPCN Major Shareholders LEXX Major Shareholders SYBX Major Shareholders PRPH Major Shareholders LSB Major Shareholders BLRX Major Shareholders This page (NASDAQ:INM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access